GNOM vs XBI: Grades, Fees and Holdings Compared

Global X Genomics & Biotechnology ETF

GNOMDNasdaq

State Street SPDR S&P Biotech ETF

XBIANYSE Arca

Overlap

21.1%by weight

Expense ratio

XBI −0.15pt a year

GNOM0.50%XBI0.35%

Avg volume · 30D

XBI 255.8×the volume

GNOM35KXBI8.95M

5Y return · a year

XBI +8.5pt

GNOM−3.8%XBI+4.7%

GNOM vs XBI Performance

Oct 29, 2021 – Oct 30, 2026

−17.5%GNOM+25.8%XBI

Expense ratio: GNOM 0.50%; XBI 0.35%, better
Fund size: GNOM $113M; XBI $10.8B
1Y total return: GNOM +55.3%, better; XBI +39.0%
Yield (12M): GNOM 0.93%, better; XBI 0.35%
Holdings: GNOM 50; XBI 164
Avg volume (30D): GNOM 35K sh; XBI 8.95M sh, better
NAV per share: GNOM $69.50; XBI $157.82
52W range

ETF.net Grade

Pillar letters and Scores for GNOM, XBI, with each pillar’s weight
Pillar	GNOM	XBI
Cost30% weight	D38	A81Higher
Mission25% weight	Not scored	A85
Risk15% weight	D28	C47Higher
Tradability15% weight	C50	A99Higher
Holdings10% weight	D37	A88Higher
Durability5% weight	C50	A89Higher

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. GNOM and XBI are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

XBI ranks 1st and GNOM 14th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 13DHELXFranklin Genomic Advancements ETFScore 39
Rank 14DGNOMGlobal X Genomics & Biotechnology ETFScore 38
Rank 15DARKGARK Genomic Revolution ETFScore 33

Our read on each fund

ETF.net Research

GNOMDGlobal X Genomics & Biotechnology ETF

XBIAState Street SPDR S&P Biotech ETF

In short

GNOM Most biotech ETFs buy the whole drug industry. GNOM buys the genome: gene editing, sequencing, genetic therapies, computational genomics. About 50 global names, one idea, no hedging.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

GNOM GNOM seeks to track, before expenses, the performance of the Solactive Genomics Index by investing in companies positioned to benefit from advances in genomic science, including gene editing, sequencing, genetic therapies, computational genomics, and biotechnology.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

GNOM A genuine pure play. The index targets companies tied to advances in genomic science (gene editing, sequencing, genetic therapies), not the broad pharma complex most biotech funds hold.globalxetfs.com
Concentrated on purpose: roughly 50 holdings, global reach. The theme drives the fund instead of being diluted by megacap drugmakers.globalxetfs.com
Running since 2019, it is one of the older dedicated genomics baskets, with a multi-year record through a full cycle in the theme.

XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

GNOM The narrow screen costs more: 0.50% a year, against 0.44% for IBB, 0.35% for XBI and 0.19% for IBBQ, which own biotech broadly.
Thinly traded next to the big biotech funds. Limit orders and mid-session trading matter more here than with a household-name ETF.
Small, clinical-stage genomics names swing hard, and with about 50 holdings there is nowhere to hide. Volatility is the price of the pure theme.

XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.com nasdaqomx.com
Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full GNOM profile⁠

Full XBI profile⁠

GNOM vs XBI Holdings

As of Oct 13, 2026

How GNOM and XBI differ

Overlap by weight

21.1%

Shared holdings make up 51.9% of GNOM and 21.1% of XBI.

Level by level

Holdings22 in both21.1%
Countryby domicile98.4%
Sector3 Sectors99.3%
Asset classEquity100%

Sector

Sector weights in GNOM and XBI, widest gap first
Sector	More in GNOMMore in XBI	GNOM	XBI
Financials	XBI +0.7 points	0.0%	0.7%
Health Care	GNOM +0.4 points	99.7%	99.3%
Technology	GNOM +0.3 points	0.3%	0.0%

Country, concentration and asset class

Country by domicile

Country weights in GNOM and XBI, widest gap first
Country	More in GNOMMore in XBI	GNOM	XBI
United States	XBI +1.4 points	95.3%	96.7%
Switzerland	GNOM +1.2 points	2.5%	1.4%
Other countries (4)	GNOM +0.3 points	2.1%	1.9%

Concentration

Weight in the 10 largest Holdings

GNOM55.7%
XBI18.0%

Securities held

GNOM50
XBI163

Asset class

GNOM: Equity
XBI: Equity

Holdings

Only in GNOM28
In both22
Only in XBI141

Only in GNOM

28 securities, 48.1% of GNOM by weight

10X Genomics Inc-Class A6.38%
Illumina Inc6.09%
Guardant Health Inc5.22%
Genscript Biotech Corp4.58%
Bio-Techne Corp3.56%
Qiagen N.v.3.26%
Caris Life Sciences Inc2.68%
Biontech Se-Adr2.54%
Legend Biotech Corp-Adr1.97%
Eli Lilly & Co1.83%
Billiontoone Inc Class A1.38%
Genedx Holdings Corp1.23%
Astrazeneca PLC1.16%
Danaher Corp1.06%
Bristol-Myers Squibb Co0.87%
Personalis Inc0.81%
Maravai Lifesciences Hldgs-A0.56%
Pacific Biosciences of Calif0.43%
Wave Life Sciences Inc0.38%
Agilent Technologies Inc0.36%
Fulgent Genetics Inc0.32%
Bruker Corp0.31%
Mesa Laboratories Inc0.27%
Quest Diagnostics Inc0.25%
Benitec Biopharma Inc0.22%
Rocket Pharmaceuticals Inc0.19%
Standard Biotools Inc0.15%
Caribou Biosciences Inc0.05%

Only in XBI

141 securities, 78.9% of XBI by weight

Halozyme Therapeutics Inc1.75%
Biogen Inc1.70%
Amgen Inc1.69%
United Therapeutics Corp1.68%
AbbVie Inc1.66%
Spyre Therapeutics Inc1.63%
Exelixis Inc1.63%
Tg Therapeutics Inc1.52%
Oruka Therapeutics Inc1.52%
Grail Inc1.51%
Regeneron Pharmaceuticals1.45%
Alkermes PLC1.43%
Protagonist Therapeutics Inc1.42%
Ptc Therapeutics Inc1.37%
Neurocrine Biosciences Inc1.35%
Krystal Biotech Inc1.34%
Bridgebio Pharma Inc1.33%
Incyte Corp1.33%
Revolution Medicines Inc1.31%
Roivant Sciences Ltd1.29%
Kymera Therapeutics Inc1.27%
Kodiak Sciences Inc1.25%
Insmed Inc1.24%
Cytokinetics Inc1.23%
Erasca Inc1.22%
Cogent Biosciences Inc1.21%
Vaxcyte Inc1.21%
Ionis Pharmaceuticals Inc1.14%
Madrigal Pharmaceuticals Inc1.13%
Dianthus Therapeutics Inc1.11%
Travere Therapeutics Inc1.10%
Rhythm Pharmaceuticals Inc1.07%
Iovance Biotherapeutics Inc1.04%
Mirum Pharmaceuticals Inc1.03%
Immunitybio Inc0.99%
Alnylam Pharmaceuticals Inc0.97%
Cg Oncology Inc0.95%
Arcutis Biotherapeutics Inc0.94%
Relay Therapeutics Inc0.92%
Viking Therapeutics Inc0.90%
Tango Therapeutics Inc0.89%
Celcuity Inc0.81%
Scholar Rock Holding Corp0.78%
Dyne Therapeutics Inc0.72%
Hyperliquid Strategies0.72%
Recursion Pharmaceuticals A0.68%
Agios Pharmaceuticals Inc0.62%
Immunovant Inc0.61%
Viridian Therapeutics Inc0.60%
Biohaven Ltd0.59%

Weight gaps

All 22 Holdings in both funds, largest gap first.

Holding weights in GNOM and XBI, widest gap first
Holding	More in GNOMMore in XBI	GNOM	XBI
Moderna IncMRNA	GNOM +8.69 points	11.05%	2.36%
Twist Bioscience CorpTWST	GNOM +4.72 points	6.70%	1.98%
Natera IncNTRA	GNOM +3.61 points	5.50%	1.89%
Vertex Pharmaceuticals IncVRTX	GNOM +1.84 points	3.33%	1.49%
Biomarin Pharmaceutical IncBMRN	GNOM +1.66 points	2.94%	1.28%
Veracyte IncVCYT	GNOM +1.39 points	2.57%	1.18%
Arrowhead Pharmaceuticals InARWR	GNOM +1.31 points	2.36%	1.05%
Caredx IncCDNA	GNOM +1.25 points	2.17%	0.92%
Crispr Therapeutics AGCRSP	GNOM +1.20 points	2.63%	1.43%
Praxis Precision Medicines IPRAX	GNOM +0.94 points	2.14%	1.20%
Beam Therapeutics IncBEAM	GNOM +0.79 points	1.75%	0.96%
Sarepta Therapeutics IncSRPT	GNOM +0.76 points	1.31%	0.55%
Vir Biotechnology IncVIR	GNOM +0.69 points	0.98%	0.29%
Stoke Therapeutics IncSTOK	GNOM +0.50 points	0.84%	0.34%
Intellia Therapeutics IncNTLA	GNOM +0.51 points	1.06%	0.55%
Uniqure NVQURE	GNOM +0.41 points	0.91%	0.50%
Ultragenyx Pharmaceutical InRARE	GNOM +0.24 points	1.07%	0.83%
Regenxbio IncRGNX	GNOM +0.13 points	0.27%	0.14%
Myriad Genetics IncMYGN	GNOM +0.10 points	0.28%	0.18%
Editas Medicine IncEDIT	GNOM +0.08 points	0.20%	0.12%
Prime Medicine IncPRME	GNOM +0.08 points	0.26%	0.18%
Gilead Sciences IncGILD	Same weight	1.63%	1.63%

All 50 GNOM holdings⁠All 165 XBI holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

GNOM vs XBI Cost

Overpaying GNOM vs XBI

$2,853

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

GNOM 0.50%
$9,979
XBI 0.35%
$7,126

Amount$10,000

Years30 years

Cost over time

GNOM 0.50%
XBI 0.35%
Overpaying

Year by year

Year	GNOM	XBI	Overpaying
10	$900	$634	$266
20	$3,460	$2,454	$1,006
30	$9,979	$7,126	$2,853

Expense ratio

0.50%GNOM
0.35%XBI, cheaper

XBI0.35%GNOM0.50%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

XBI 3rd cheapest of 17 funds

GNOM 10th cheapest of 17 funds

GNOM vs XBI Dividends

Last 12 months to Oct 30, 2026

Yield (12M): GNOM 0.93%, better; XBI 0.35%
Payout (12M): GNOM $0.65; XBI $0.54
Last payment: GNOM $0.06; XBI $0.14
Ex-dividend: GNOM Jun 29, 2026; XBI Jun 22, 2026
Paid on: GNOM Jul 7, 2026; XBI Jun 24, 2026
Frequency: GNOM Twice a year; XBI Twice a year

Distribution history

Per share, 2017 to 2026, same scale for both

GNOMTwice a year · 5 paymentsAll GNOM payments⁠

XBITwice a year · 24 paymentsAll XBI payments⁠

GNOM vs XBI Risk

Fall from peak · 5 years

GNOM
XBI

Risk facts

VolatilityStd dev, 3 years: GNOM 30.0%XBI 24.8%, better
Return per unit of riskSharpe ratio, 3 years: GNOM 0.77XBI 1.11, better
Worst fallMax drawdown, 5 years: GNOM −68.9%XBI −53.2%, better
Market sensitivityBeta, 5 years: GNOM 1.60XBI 1.10; Market = 1

GNOM and XBI in the news

All news⁠

Deep Dive
Moderna fell 18% on cancer-vaccine data, and genomics ETFs fell 4%
Oct 23, 2026GNOMXBI
Top Movers
iShares MSCI Indonesia ETF EIDO jumps 7.2% as Jakarta rebounds
Oct 20, 2026XBI
Closing Bell
Investors rotate out of tech as health care hits a record; Dow gains 1%
Oct 20, 2026XBI
Top Movers
Constellation rose 12% on Google's nuclear deal, and genomics funds sank
Oct 6, 2026XBI
Top Movers
Fair Isaac fell 26.5% after a rival score joined Fannie and Freddie's fee grid
Sep 29, 2026XBI
News
AstraZeneca agrees to invest $2 billion in Summit, without the drug rights
Sep 28, 2026XBI

Popular comparisons

GNOMDvsIBBQA
Global X Genomics & Biotechnology ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.50% · 0.19%
Category
XBIAvsIBBQA
State Street SPDR S&P Biotech ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.35% · 0.19%
Category
GNOMDvsIBBA
Global X Genomics & Biotechnology ETF · iShares Biotechnology ETF
Expense ratio
0.50% · 0.44%
Category
XBIAvsIBBA
State Street SPDR S&P Biotech ETF · iShares Biotechnology ETF
Expense ratio
0.35% · 0.44%
Category
GNOMDvsBBPA
Global X Genomics & Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.50% · 0.34%
Category
XBIAvsBBPA
State Street SPDR S&P Biotech ETF · Virtus Biotech ETF
Expense ratio
0.35% · 0.34%
Category